keyword
MENU ▼
Read by QxMD icon Read
search

Prostate biopsy

keyword
https://www.readbyqxmd.com/read/29456227/a-case-of-renal-granulomatosis-with-polyangiitis-following-intravesical-bacillus-calmette-gu%C3%A3-rin-therapy
#1
Yosra Selmi, Rania Kheder-Elfekih, Hela Jebali, Lilia Ben Fatma, Wided Smaoui, Madiha Krid, Soumaya Beji, Lamia Rais, Mohamed Karim Zouaghi
Various adverse reactions may occur after intravesical bacillus Calmette-Guérin (BCG) therapy. Although the virulence of attenuated BCG is low, serious complications such as bacterial cystitis, bladder contractures, granulomatous prostatitis, epididymitis, orchitis, and systemic reactions such as fever and malaise have been described. Disseminated granulomatosis such as hepatitis and pneumonitis have also been described, but are rare. We report here the case of a 67-year-old patient who presented with renal granulomatosis with polyangiitis following intravesical BCG therapy for superficial bladder tumor...
January 2018: Saudi Journal of Kidney Diseases and Transplantation
https://www.readbyqxmd.com/read/29453690/the-effectiveness-of-targeted-relative-to-empiric-prophylaxis-on-infectious-complications-after-transrectal-ultrasound-guided-prostate-biopsy-a-meta-analysis
#2
REVIEW
Susan Scott, Patrick N Harris, Deborah A Williamson, Michael A Liss, Suhail A R Doi, Matthew J Roberts
PURPOSE: Rectal culture screening for fluoroquinolone (FQ)-resistant Enterobacteriaceae before transrectal ultrasound guided prostate (TRUSPB) biopsy and targeted antibiotic prophylaxis (TAP) may decrease post-TRUSPB infection rates compared to empiric (EAP) regimens. The objective of this study was to evaluate the effectiveness of targeted relative to empiric prophylaxis regimens on rates of infectious complications after TRUSPB and to determine the baseline prevalence of FQ resistance based on prior rectal swabs...
February 16, 2018: World Journal of Urology
https://www.readbyqxmd.com/read/29453511/developing-new-age-specific-prostate-specific-antigen-thresholds-for-testing-for-prostate-cancer
#3
Rebecca Gilbert, Kate Tilling, Richard M Martin, J Athene Lane, Michael Davis, Freddie C Hamdy, David E Neal, Jenny L Donovan, Chris Metcalfe
PURPOSE: To examine whether age-related reference ranges for "normal" prostate-specific antigen (PSA) change (determined in men without prostate cancer) can be used to identify men at high risk of having prostate cancer. METHODS: Subjects were men aged 50-69 years with PSA < 10 ng/mL from the UK-based Prostate Testing for cancer and Treatment (ProtecT) study. Men with prostate cancer were categorized as high or low risk of progression (Low risk: Gleason score ≤ 6 and stage T1-T2a; High risk: Gleason score 7-10 or stage T2C)...
February 16, 2018: Cancer Causes & Control: CCC
https://www.readbyqxmd.com/read/29453313/multigene-profiling-of-ctcs-in-mcrpc-identifies-a-clinically-relevant-prognostic-signature
#4
Udit Singhal, Yugang Wang, James Henderson, Yashar S Niknafs, Yuanyuan Qiao, Amy Gursky, Alexander Zaslavsky, Jae-Seung Chung, David C Smith, R Jeffrey Karnes, S Laura Chang, Felix Y Feng, Ganesh S Palapattu, Russell S Taichman, Arul M Chinnaiyan, Scott A Tomlins, Todd M Morgan
The trend towards precision-based therapeutic approaches dictated by molecular alterations offers substantial promise for men with metastatic castration resistant prostate cancer (mCRPC). However, current approaches for molecular characterization are primarily tissue based, necessitating serial biopsies to understand changes over time and are limited by the challenges inherent to extracting genomic material from predominantly bone metastases. Therefore, a circulating tumor cell (CTC)-based assay was developed to determine gene expression across a panel of clinically relevant and potentially actionable prostate cancer related genes...
February 16, 2018: Molecular Cancer Research: MCR
https://www.readbyqxmd.com/read/29446205/surgeon-led-prostate-cancer-lymph-node-staging-pathologic-outcomes-stratified-by-robot-assisted-dissection-templates-and-patient-selection
#5
Muammer Altok, Kara Babaian, Mary F Achim, Grace C Achim, Patricia Troncoso, Surena F Matin, Brian F Chapin, John W Davis
OBJECTIVES: To evaluate the peri-operative, pathologic, and oncologic outcomes from surgeon led pathologic staging of pelvic lymph node metastases at the time of robot-assisted radical prostatectomy (RARP). PATIENTS AND METHODS: Over the 6-year period of 2006-2012, three distinct pelvic lymph node dissection strategies were utilized in chronologic order at a single cancer referral hospital. Strategies were characterized by both a 1) omission of PLND versus inclusion decision threshold, and 2) standard versus extended templates for patients selected for PLND...
February 15, 2018: BJU International
https://www.readbyqxmd.com/read/29443386/technical-note-error-metrics-for-estimating-the-accuracy-of-needle-instrument-placement-during-transperineal-mr-us-guided-prostate-interventions
#6
Ester Bonmati, Yipeng Hu, Barbara Villarini, Rachael Rodell, Paul Martin, Lianghao Han, Ian Donaldson, Hashim U Ahmed, Caroline M Moore, Mark Emberton, Dean C Barratt
PURPOSE: Image-guided systems that fuse magnetic resonance imaging (MRI) with three-dimensional (3D) ultrasound (US) images for performing targeted prostate needle biopsy and minimally-invasive treatments for prostate cancer are of increasing clinical interest. To date, a wide range of different accuracy estimation procedures and error metrics have been reported, which makes comparing the performance of different systems difficult. METHODS: A set of 9 measures are presented to assess the accuracy of MRI-US image registration, needle positioning, needle guidance, and overall system error, with the aim of providing a methodology for estimating the accuracy of instrument placement using a MR/US-guided transperineal approach...
February 14, 2018: Medical Physics
https://www.readbyqxmd.com/read/29439715/skene-duct%C3%A2-adenocarcinoma-in-a-patient-with-an-elevated-serum-prostate-specific-antigen-level-a-case-report
#7
Sohgo Tsutsumi, Takashi Kawahara, Yusuke Hattori, Taku Mochizuki, Jun-Ichi Teranishi, Kazuhide Makiyama, Yasuhide Miyoshi, Masako Otani, Hiroji Uemura
BACKGROUND: Female urethral carcinoma is a very rare disease that accounts for 0.02% of malignant diseases in female patients. CASE PRESENTATION: A 70-year-old Asian Japanese woman with a urethral tumor was referred to our hospital to undergo further examination. Biopsy specimens showed urethral adenocarcinoma that was positive for prostate-specific antigen. Her serum prostate-specific antigen level before surgery was 34.4 ng/ml. Urethral tumor resection with pelvic lymph node resection was performed...
February 14, 2018: Journal of Medical Case Reports
https://www.readbyqxmd.com/read/29439298/a-rare-cause-of-pancreatic-head-mass-metastatic-prostate-cancer-a-case-report-and-review-of-literature
#8
Khalil Aloreidi, Robert T Lapp
Metastases to the pancreas account for less than 5 percent of all malignancies affecting the pancreas. The most common secondary malignancy of the pancreas is renal cell carcinoma. We report a patient presented with abdominal pain and weight loss. Computed tomography (CT) imaging showed pancreatic head mass. Biopsy from the mass showed prostate metastasis after 13 years from radical prostatectomy and Leuprolide therapy. This case demonstrates a rare location for prostate metastasis which was the pancreas. To our knowledge there are only six cases reported in literature...
January 2018: South Dakota Medicine: the Journal of the South Dakota State Medical Association
https://www.readbyqxmd.com/read/29438586/progression-and-treatment-rates-using-an-active-surveillance-protocol-incorporating-image-guided-baseline-biopsies-and-multi-parametric-mri-monitoring-for-men-with-favourable-risk-prostate-cancer
#9
David Thurtle, Tristan Barrett, Vineetha Thankappan-Nair, Brendan Koo, Anne Warren, Christof Kastner, Kasra Saeb-Parsy, Jenna Kimberley-Duffell, Vincent J Gnanapragasam
OBJECTIVE: To assess early outcomes since the introduction of an active surveillance (AS) protocol incorporating mpMRI guided baseline biopsies and image based surveillance. PATIENTS AND METHODS: A new AS protocol mandating image-guided baseline biopsies, annual mpMRI and 3 monthly PSA but which retained protocol re-biopsies was tested. Pathological progression, treatment conversion and triggers for non-protocol biopsy were recorded prospectively. RESULTS: Data from 157 men enrolled on this protocol (median: age 64years, PSA 6...
February 13, 2018: BJU International
https://www.readbyqxmd.com/read/29437268/using-support-vector-machine-analysis-to-assess-partinmr-a-new-prediction-model-for-organ-confined-prostate-cancer
#10
Jing Wang, Chen-Jiang Wu, Mei-Ling Bao, Jing Zhang, Hai-Bin Shi, Yu-Dong Zhang
BACKGROUND: Partin tables represent the most widely used predictive tool for prostate cancer stage at prostatectomy but with potential limitations. PURPOSE: To develop a new PartinMR model for organ-confined prostate cancer (OCPCA) by incorporating Partin table and mp-MRI with a support vector machine (SVM) analysis. STUDY TYPE: Retrospective. POPULATION: In all, 541 patients with biopsy-confirmed prostate cancer underwent mp-MRI...
February 13, 2018: Journal of Magnetic Resonance Imaging: JMRI
https://www.readbyqxmd.com/read/29437039/microrna-1246-is-an-exosomal-biomarker-for-aggressive-prostate-cancer
#11
Divya Bhagirath, Thao Ly Yang, Nathan Bucay, Kirandeep Sekhon, Shahana Majid, Varahram Shahryari, Rajvir Dahiya, Yuichiro Tanaka, Sharanjot Saini
Due to high heterogeneity, molecular characterization of prostate cancer (PCa) based on biopsy sampling is often challenging. Hence, a minimally invasive method to determine the molecular imprints of a patient's tumor for risk stratification would be advantageous. In this study, we employ a novel, digital amplification-free quantification method using the nCounter technology (Nanostring Technologies) to profile exosomal serum miRNAs (ex-miRNA) from aggressive PCa cases, benign prostatic hyperplasia (BPH), and disease-free controls...
February 1, 2018: Cancer Research
https://www.readbyqxmd.com/read/29436189/prostate-specific-antigen-kinetics-following-5%C3%AE-reductase-inhibitor-treatment-may-be-a-useful-indicator-for-repeat-prostate-biopsy
#12
Ji Eun Heo, Kyo Chul Koo, Sung Joon Hong, Sang Un Park, Byung Ha Chung, Kwang Suk Lee
PURPOSE: To evaluate parameters for determining repeat prostate biopsy in patients with 5α-reductase inhibitor (5ARI) treatment after initial negative biopsy. MATERIALS AND METHODS: From January 2007 to December 2015, patients who underwent a repeat prostate biopsy after an initial negative biopsy were enrolled from multiple institutions. Serial prostate-specific antigen (PSA) levels after the initial biopsy were analyzed for PSA kinetics. Clinicopathologic variables were evaluated according to the use of 5ARIs after the initial negative biopsy...
March 2018: Yonsei Medical Journal
https://www.readbyqxmd.com/read/29433987/poor-follow-up-after-elevated-prostate-specific-antigen-tests-a-population-based-cohort-study
#13
Markus Aly, Mark Clements, Caroline E Weibull, Tobias Nordström, Erik Näslund, Jan Adolfsson, Henrik Grönberg
BACKGROUND: Although prostate-specific antigen (PSA) testing is common, little is known about the pattern of retesting by either PSA values or subsequent prostate biopsies. Poor follow-up of high PSA values may lead to delayed diagnosis. OBJECTIVE: To estimate the probabilities of follow-up (including retesting, prostate biopsies, diagnosis, and cause-specific death) for men undergoing prostate cancer testing at a population level. DESIGN, SETTING, AND PARTICIPANTS: Cohort study design for men living in Stockholm with no previous diagnosis of prostate cancer between 2003 and 2015...
February 9, 2018: European Urology Focus
https://www.readbyqxmd.com/read/29433975/refined-analysis-of-prostate-specific-antigen-kinetics-to-predict-prostate-cancer-active-surveillance-outcomes
#14
Matthew R Cooperberg, James D Brooks, Anna V Faino, Lisa F Newcomb, James T Kearns, Peter R Carroll, Atreya Dash, Ruth Etzioni, Michael D Fabrizio, Martin E Gleave, Todd M Morgan, Peter S Nelson, Ian M Thompson, Andrew A Wagner, Daniel W Lin, Yingye Zheng
BACKGROUND: For men on active surveillance for prostate cancer, utility of prostate-specific antigen (PSA) kinetics (PSAk) in predicting pathologic reclassification remains controversial. OBJECTIVE: To develop prediction methods for utilizing serial PSA and evaluate frequency of collection. DESIGN, SETTING, AND PARTICIPANTS: Data were collected from men enrolled in the multicenter Canary Prostate Active Surveillance Study, for whom PSA data were measured and biopsies performed on prespecified schedules...
February 9, 2018: European Urology
https://www.readbyqxmd.com/read/29433973/role-of-surveillance-biopsy-with-no-cancer-as-a-prognostic-marker-for-reclassification-results-from-the-canary-prostate-active-surveillance-study
#15
James T Kearns, Anna V Faino, Lisa F Newcomb, James D Brooks, Peter R Carroll, Atreya Dash, William J Ellis, Michael Fabrizio, Martin E Gleave, Todd M Morgan, Peter S Nelson, Ian M Thompson, Andrew A Wagner, Yingye Zheng, Daniel W Lin
BACKGROUND: Many patients who are on active surveillance (AS) for prostate cancer will have surveillance prostate needle biopsies (PNBs) without any cancer evident. OBJECTIVE: To define the association between negative surveillance PNBs and risk of reclassification on AS. DESIGN, SETTING, AND PARTICIPANTS: All men were enrolled in the Canary Prostate Active Surveillance Study (PASS) between 2008 and 2016. Men were included if they had Gleason ≤3+4 prostate cancer and <34% core involvement ratio at diagnosis...
February 9, 2018: European Urology
https://www.readbyqxmd.com/read/29432341/rare-case-of-intratracheal-metastasis-detected-on-68ga-prostate-specific-membrane-antigen-pet-ct-scan-in-a-case-of-thyroglobulin-elevated-negative-iodine-scan-syndrome
#16
Arun Sasikumar, Ajith Joy, M R A Pillai, Karuna Elza Oommen, R Jayakumar
A 64-year-old woman underwent completion thyroidectomy with upper tracheal ring resection and right-sided neck dissection for papillary carcinoma of the thyroid infiltrating the trachea and was given I radioiodine treatment. Three years later, she presented with hemoptysis. On evaluation, she had increased serum thyroglobulin and negative iodine scan (TENIS). F-FDG PET/CT scan did not identify any site of disease. One year later, Ga-PSMA scan done revealed a moderate focal tracer-avid intratracheal soft tissue; biopsy revealed it to be metastatic papillary carcinoma of the thyroid...
February 9, 2018: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/29432339/18f-choline-pet-mr-can-detect-and-delineate-local-recurrence-after-high-intensity-focused-ultrasound-therapy-of-prostate-cancer
#17
Irene A Burger, Andrei Gafita, Julian Müller, Benedikt Kranzbühler, Olivio F Donati, Daniel Eberli
Restaging local recurrence after high-intensity focused ultra-sound (HIFU) is based on multiparametric MRI (mpMRI). However, postinterventional changes of the tissue, such as edema or hemorrhage, are limiting tumor detection on mpMRI. We present a case of a rising prostate-specific antigen values, negative mpMRI, and a Gleason score of 4+4 on template biopsy after HIFU. On F-choline PET/MR, high focal uptake was detected at the location of positive biopsy. Re-HIFU based on the fused F-choline PET/MR images was performed, followed by a recurrence-free period of 11 months...
February 9, 2018: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/29429896/metabolic-syndrome-is-not-associated-with-greater-evidences-of-proliferative-inflammatory-atrophy-and-inflammation-in-patients-with-suspected-prostate-cancer
#18
Giorgio I Russo, Sebastiano Cimino, Giorgia Giranio, Federica Regis, Vincenzo Favilla, Salvatore Privitera, Fabio Motta, Rosario Caltabiano, Arnulf Stenzl, Tilman Todenhöfer, Giuseppe Morgia
INTRODUCTION AND OBJECTIVES: To evaluate the association between metabolic syndrome (MetS) and proliferative inflammatory atrophy (PIA) in patients with suspected prostate cancer (PCa). PATIENTS AND METHODS: From June 2015 to July 2016, we conducted the FIERY (Flogosis Increased Events of pRostatic biopsY) study at the Urology section, Department of Surgery of the University of Catania (Local registration number: #131/2015). A total of 205 patients with elevated prostate-specific antigen (≥ 4 ng/ml) or clinical suspicion of PCa who underwent primary transperineal prostate biopsy were included in this cross-sectional study...
February 8, 2018: Urologic Oncology
https://www.readbyqxmd.com/read/29428182/online-interactive-case-based-instruction-in-prostate-magnetic-resonance-imaging-interpretation-using-prostate-imaging-and-reporting-data-system-version-2-effect-for-novice-readers
#19
Andrew B Rosenkrantz, Jovan Begovic, Antonio Pires, Eugene Won, Samir S Taneja, James S Babb
PURPOSE: To assess the effect on reader performance of an interactive case-based online tutorial for prostate magnetic resonance imaging (MRI) interpretation using Prostate Imaging and Reporting Data System (PI-RADS). METHODS: An educational website was developed incorporating scrollable multiparametric prostate MRI examinations with annotated solutions based on PI-RADS version 2. Three second-year radiology residents evaluated a separate set of 60 prostate MRI examinations both before and after review of the online case material, identifying and scoring dominant lesions...
January 10, 2018: Current Problems in Diagnostic Radiology
https://www.readbyqxmd.com/read/29422418/incorporation-of-urinary-prostate-cancer-antigen-3-and-tmprss2-erg-into-prostate-cancer-prevention-trial-risk-calculator
#20
Donna P Ankerst, Martin Goros, Scott A Tomlins, Dattatraya Patil, Ziding Feng, John T Wei, Martin G Sanda, Jonathan Gelfond, Ian M Thompson, Robin J Leach, Michael A Liss
BACKGROUND: The Prostate Cancer Prevention Trial Risk Calculator (PCPTRC) is a commonly used risk tool for predicting the outcome on biopsy based on the established risk factors. OBJECTIVE: To determine whether incorporation of the novel urinary markers prostate cancer antigen 3 (PCA3) and TMPRSS2:ERG (T2:ERG) into the PCPTRC improves its discrimination, accuracy, and clinical net benefit. DESIGN, SETTING, AND PARTICIPANTS: Since PCA3 and T2:ERG were not measured as part of the PCPTRC, a Bayesian modeling approach was used to combine data where the markers were measured in a Michigan cohort with the PCPTRC as prior probabilities to form an updated PCPTRC...
February 5, 2018: European Urology Focus
keyword
keyword
7557
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"